ORIX reports progress on 2026 share buyback
ORIX Corporation reported progress on its ongoing share repurchase program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ORIX Corporation reported progress on its ongoing share repurchase program. Between May 22 and May 31, 2026, the company bought back 1,693,600 common shares for a total of JPY 10,574,598,800 through market purchases under a discretionary dealing contract.
This buyback is part of a larger Board-authorized program, allowing repurchases of up to 100,000,000 common shares, or approximately 9.1% of outstanding shares excluding treasury stock, for up to JPY 250 billion. The program runs from May 22, 2026 to March 31, 2027, signaling a sizable capital return framework while leaving substantial capacity for additional repurchases.
Positive
- Large buyback authorization: Board approval to repurchase up to 100,000,000 common shares, approximately 9.1% of outstanding shares (excluding treasury), for up to JPY 250 billion represents a substantial capital return capacity.
Negative
- None.
Insights
ORIX is executing a sizable, multi-month share repurchase program with significant remaining capacity.
ORIX Corporation has begun acting on a Board-approved buyback of up to JPY 250 billion or 9.1% of its outstanding common shares (excluding treasury). Initial execution totals 1,693,600 shares for about JPY 10.6 billion, using market purchases under a discretionary dealing contract.
This early activity represents only a small fraction of the authorized 100,000,000 shares, so most of the buyback capacity remains available through March 31, 2027. Actual impact will depend on the pace and scale of future repurchases within the stated limits and market conditions.
Key Figures
Key Terms
Companies Act regulatory
discretionary dealing contract financial
forward-looking statements regulatory
foreign private issuer regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much has ORIX spent so far under the 2026 buyback resolution?
AI-generated analysis. How Rhea-AI works. Not financial advice.